Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh.
Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
This study is designed as an open label evaluation of the efficacy of latanoprost and timolol
fixed combination (Xalacom) after 6 month of treatment. Eligible patients may be enrolled at
the baseline visit. All current ocular hypotensive therapy must be discontinued at this time.
On baseline day, patients eligible for the study will receive Xalacom which is to be
instilled in the morning.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.